Q-omics provides the consensus-scored PLCB3 profile across patient tissues and cancer cell-line models. PLCB3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PLCB3 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, PLCB3 RNA expression shows 18,189 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, BLCA, and UVM as cancer lineages where PLCB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLCB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLCB3 survival associations across molecular data types. PLCB3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLCB3 RNA expression–survival associations across cancer types. High PLCB3 expression shows unfavorable associations in KICH, MESO, LIHC, CESC, UVM and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PLCB3 RNA expression.
This table summarizes PLCB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PLCB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLCB3 shows higher tumor expression in BLCA, HNSC, KIRP, KIRC, LIHC and LUSC. The BLCA box plot shows higher PLCB3 RNA expression in tumor versus normal tissue (log2 FC = +1.425, t-test p < 0.001).
This table shows molecular features associated with PLCB3 in patient tissues and cancer cell lines. In patient samples, PLCB3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLCB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
